With COVID-19 case counts rising amid the spread of the Delta variant, the Association for Clinical Oncology joined more than 50 health care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health care employers to require their employees to be vaccinated against COVID-19.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
On July 21, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
The Association for Clinical Oncology (ASCO) along with other health care organizations sent a letter to U.S. Senate leadership to convey their opposition to an extension of mandatory Medicare sequestration as a pay-for in any infrastructure package. The letter urges lawmakers to reconsider the potential use of Medicare funds included in the bipartisan infrastructure framework.
Members of Congress recently reintroduced the Cancer Drug Parity Act (H.R. 4385) in the U.S. House of Representatives. The bill would ensure patient cost sharing for oral and other self-administered anticancer drugs is no less favorable than for traditional intravenous (IV) medication administered in an office setting.
The Centers for Medicare & Medicaid Services (CMS) released its 2022 Hospital Outpatient Prospective Payment System (OPPS) proposed rule. Specific provisions that would impact the cancer care community are included here.
ASCO provided comments on a recently released 21st Century Cures 2.0 Act discussion draft and accompanying Advanced Research Projects Agency Health (ARPA-H) request for information (RFI).
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.
On July 13, 2021, the Centers for Medicare & Medicaid Services released its proposed rule for the 2022 Medicare Physician Fee Schedule and updates to the Quality Payment Program (QPP). The Association for Clinical Oncology (ASCO) is still analyzing the full proposal, but based on a preliminary analysis, key provisions for the cancer care community are included here.
Today, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care.
On July 9, 2021, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
On July 9, 2021, the Food and Drug Administration approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.).
In addition to the Association for Clinical Oncology’s (ASCO) advocacy at the federal level in Washington, DC, ASCO is also at work in state capitals advocating for improved patient access to high-quality, equitable cancer care at the state level.
The Department of Health and Human Services (HHS), the Department of Labor, the Department of the Treasury, and the Office of Personnel Management released an interim final rule with comment period (IFR), Requirements Related to Surprise Billing; Part I. This rule is the first of a series that will implement provisions of the No Surprises Act (NSA) signed into law as part of the 2021 COVID-19 relief bill.
On June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.